Inorganic Nanomaterials Versus Polymer-Based Nanoparticles for Overcoming Neurodegeneration

Overview

Journal Nanomaterials (Basel)

Date 2022 Jul 27

PMID 35889562

Authors

Simona Martano

Valeria De Matteis

Mariafrancesca Cascione

Rosaria Rinaldi

Affiliations

Soon will be listed here.

Abstract

Neurodegenerative disorders (NDs) affect a great number of people worldwide and also have a significant socio-economic impact on the aging population. In this context, nanomedicine applied to neurological disorders provides several biotechnological strategies and nanoformulations that improve life expectancy and the quality of life of patients affected by brain disorders. However, available treatments are limited by the presence of the blood-brain barrier (BBB) and the blood-cerebrospinal fluid barrier (B-CSFB). In this regard, nanotechnological approaches could overcome these obstacles by updating various aspects (e.g., enhanced drug-delivery efficiency and bioavailability, BBB permeation and targeting the brain parenchyma, minimizing side effects). The aim of this review is to carefully explore the key elements of different neurological disorders and summarize the available nanomaterials applied for neurodegeneration therapy looking at several types of nanocarriers. Moreover, nutraceutical-loaded nanoparticles (NPs) and synthesized NPs using green approaches are also discussed underling the need to adopt eco-friendly procedures with a low environmental impact. The proven antioxidant properties related to several natural products provide an interesting starting point for developing efficient and green nanotools useful for neuroprotection.

Citing Articles

Quercetin nanoparticles as a therapeutic approach: pharmacological actions and potential applications in therapy.

Baiomy R BioTechnologia (Pozn). 2025; 105(4):377-393.

PMID: 39844873 PMC: 11748223. DOI: 10.5114/bta.2024.145258.

Peony-shaped zinc oxide nanoflower synthesized via hydrothermal route exhibits promising anticancer and anti-amyloid activity.

Girigoswami A, Deepika B, Udayakumar S, Janani G, Jessy Mercy D, Girigoswami K BMC Pharmacol Toxicol. 2024; 25(1):101.

PMID: 39736727 PMC: 11684297. DOI: 10.1186/s40360-024-00830-x.

Green synthesis of nanoparticles using medicinal plants as an eco-friendly and therapeutic potential approach for neurodegenerative diseases: a comprehensive review.

Izadi R, Bahramikia S, Akbari V Front Neurosci. 2024; 18:1453499.

PMID: 39649663 PMC: 11621856. DOI: 10.3389/fnins.2024.1453499.

Nanomedicine in the treatment of Alzheimer's disease: bypassing the blood-brain barrier with cutting-edge nanotechnology.

Dong N, Ali-Khiavi P, Ghavamikia N, Pakmehr S, Sotoudegan F, Hjazi A Neurol Sci. 2024; .

PMID: 39638950 DOI: 10.1007/s10072-024-07871-4.

Advancements in Engineering Planar Model Cell Membranes: Current Techniques, Applications, and Future Perspectives.

Coronado S, Herrera J, Pino M, Martin S, Ballesteros-Rueda L, Cea P Nanomaterials (Basel). 2024; 14(18).

PMID: 39330645 PMC: 11434481. DOI: 10.3390/nano14181489.

References

Chen S, Han Y, Huang J, Dai L, Du J, McClements D . Fabrication and Characterization of Layer-by-Layer Composite Nanoparticles Based on Zein and Hyaluronic Acid for Codelivery of Curcumin and Quercetagetin. ACS Appl Mater Interfaces. 2019; 11(18):16922-16933. DOI: 10.1021/acsami.9b02529. View

Gonzalez-Sarrias A, Nunez-Sanchez M, Tomas-Barberan F, Espin J . Neuroprotective Effects of Bioavailable Polyphenol-Derived Metabolites against Oxidative Stress-Induced Cytotoxicity in Human Neuroblastoma SH-SY5Y Cells. J Agric Food Chem. 2017; 65(4):752-758. DOI: 10.1021/acs.jafc.6b04538. View

Smith A, Giunta B, Bickford P, Fountain M, Tan J, Shytle R . Nanolipidic particles improve the bioavailability and alpha-secretase inducing ability of epigallocatechin-3-gallate (EGCG) for the treatment of Alzheimer's disease. Int J Pharm. 2010; 389(1-2):207-12. PMC: 5831366. DOI: 10.1016/j.ijpharm.2010.01.012. View

Dadfar S, Roemhild K, Drude N, von Stillfried S, Knuchel R, Kiessling F . Iron oxide nanoparticles: Diagnostic, therapeutic and theranostic applications. Adv Drug Deliv Rev. 2019; 138:302-325. PMC: 7115878. DOI: 10.1016/j.addr.2019.01.005. View

Liu G, Men P, Kudo W, Perry G, Smith M . Nanoparticle-chelator conjugates as inhibitors of amyloid-beta aggregation and neurotoxicity: a novel therapeutic approach for Alzheimer disease. Neurosci Lett. 2009; 455(3):187-90. PMC: 2683427. DOI: 10.1016/j.neulet.2009.03.064. View

Aalinkeel R, Kutscher H, Singh A, Cwiklinski K, Khechen N, Schwartz S . Neuroprotective effects of a biodegradable poly(lactic-co-glycolic acid)-ginsenoside Rg3 nanoformulation: a potential nanotherapy for Alzheimer's disease?. J Drug Target. 2017; 26(2):182-193. DOI: 10.1080/1061186X.2017.1354002. View

Bi C, Wang A, Chu Y, Liu S, Mu H, Liu W . Intranasal delivery of rotigotine to the brain with lactoferrin-modified PEG-PLGA nanoparticles for Parkinson's disease treatment. Int J Nanomedicine. 2016; 11:6547-6559. PMC: 5153272. DOI: 10.2147/IJN.S120939. View

Mitchell M, Billingsley M, Haley R, Wechsler M, Peppas N, Langer R . Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2020; 20(2):101-124. PMC: 7717100. DOI: 10.1038/s41573-020-0090-8. View

Rautio J, Laine K, Gynther M, Savolainen J . Prodrug approaches for CNS delivery. AAPS J. 2008; 10(1):92-102. PMC: 2751454. DOI: 10.1208/s12248-008-9009-8. View

10.

Baysal I, Ucar G, Gultekinoglu M, Ulubayram K, Yabanoglu-Ciftci S . Donepezil loaded PLGA-b-PEG nanoparticles: their ability to induce destabilization of amyloid fibrils and to cross blood brain barrier in vitro. J Neural Transm (Vienna). 2016; 124(1):33-45. DOI: 10.1007/s00702-016-1527-4. View

11.

Ahlawat J, Neupane R, Deemer E, Sreenivasan S, Narayan M . Chitosan-Ellagic Acid Nanohybrid for Mitigating Rotenone-induced Oxidative Stress. ACS Appl Mater Interfaces. 2020; 12(16):18964-18977. DOI: 10.1021/acsami.9b21215. View

12.

Di Stefano A, Iannitelli A, Laserra S, Sozio P . Drug delivery strategies for Alzheimer's disease treatment. Expert Opin Drug Deliv. 2011; 8(5):581-603. DOI: 10.1517/17425247.2011.561311. View

13.

Chen S, Han Y, Sun C, Dai L, Yang S, Wei Y . Effect of molecular weight of hyaluronan on zein-based nanoparticles: Fabrication, structural characterization and delivery of curcumin. Carbohydr Polym. 2018; 201:599-607. DOI: 10.1016/j.carbpol.2018.08.116. View

14.

Kabanov A, Gendelman H . Nanomedicine in the diagnosis and therapy of neurodegenerative disorders. Prog Polym Sci. 2010; 32(8-9):1054-1082. PMC: 2838200. DOI: 10.1016/j.progpolymsci.2007.05.014. View

15.

Sun D, Li N, Zhang W, Zhao Z, Mou Z, Huang D . Design of PLGA-functionalized quercetin nanoparticles for potential use in Alzheimer's disease. Colloids Surf B Biointerfaces. 2016; 148:116-129. DOI: 10.1016/j.colsurfb.2016.08.052. View

16.

Zhou Y, Li H, Lu L, Fu D, Liu A, Li J . Ginsenoside Rg1 provides neuroprotection against blood brain barrier disruption and neurological injury in a rat model of cerebral ischemia/reperfusion through downregulation of aquaporin 4 expression. Phytomedicine. 2014; 21(7):998-1003. DOI: 10.1016/j.phymed.2013.12.005. View

17.

Zhou K, Motamed S, Thouas G, Bernard C, Li D, Parkington H . Graphene Functionalized Scaffolds Reduce the Inflammatory Response and Supports Endogenous Neuroblast Migration when Implanted in the Adult Brain. PLoS One. 2016; 11(3):e0151589. PMC: 4792446. DOI: 10.1371/journal.pone.0151589. View

18.

Wilson B, Geetha K . Neurotherapeutic applications of nanomedicine for treating Alzheimer's disease. J Control Release. 2020; 325:25-37. DOI: 10.1016/j.jconrel.2020.05.044. View

19.

Modi G, Pillay V, Choonara Y, Ndesendo V, du Toit L, Naidoo D . Nanotechnological applications for the treatment of neurodegenerative disorders. Prog Neurobiol. 2009; 88(4):272-85. DOI: 10.1016/j.pneurobio.2009.05.002. View

20.

Gust D, Moore T, Moore A . Photochemistry of supramolecular systems containing C60. J Photochem Photobiol B. 2001; 58(2-3):63-71. DOI: 10.1016/s1011-1344(00)00145-7. View